Sequana Medical – Executive Interview

Published on 15 November 2022

Based in Belgium, Sequana Medical develops and commercialises products to treat diuretic-resistant fluid overload, a frequent complication of liver disease and heart failure. Its proprietary alfapump and DSR approaches aim to provide significant clinical and quality-of-life benefits in these fluid overload conditions.

In this interview, chief executive officer Ian Crosbie describes the recently reported positive efficacy data from its POSEIDON North American registration study for the alfapump device in recurrent and refractory ascites, and the next steps planned prior to commercialisation in the region. Mr Crosbie also highlights the company’s recent activities and the upcoming development strategy for its DSR 2.0 product, which is being advanced to treat fluid overload in heart failure patients.

Share this with friends and colleagues